Scholarlink

Introduction <p>Secukinumab has demonstrated sustained efficacy and a favorable safety profile in clinical trials, providing relief from psoriatic symptoms.</p> Objective <p>To assess the long-term, real-world retention, effectiveness, and safety of secukinumab in routine clinical practice for the treatment of moderate to severe plaque psoriasis (PsO).</p> Methods <p>SERENA (CAIN457A3403) is a longitudinal, observational study conducted at 438 sites and 19 countries for up to 5&#xa0;years in adult patients with moderate to severe PsO, psoriatic arthritis, and ankylosing spondylitis. Patients received secukinumab treatment for ≥ 16&#xa0;weeks before enrollment. This manuscript presents the 5-year data from the SERENA study in patients with moderate to severe PsO.</p> Results <p>Overall, 1740 patients (67.5% male), with a mean age of 48.3&#xa0;years and mean body mass index of 28.8&#xa0;kg/m<sup>2</sup>, were included in the analysis. The estimated secukinumab retention rates were 88.5%, 76.3%, 68.6%, 63.1%, and 58.5% at years 1, 2, 3, 4, and 5, respectively. For the 913 patients who discontinued the study, the most common reasons included lack of efficacy (25.4%), patient decision (7.6%), physician decision (5.5%), and loss to follow-up (4.8%). The mean ± standard deviation (SD) absolute Psoriasis Area and Severity Index (PASI) score was 21.1 ± 13.0 at treatment initiation (<i>n</i> = 1545). At enrollment, the mean ± SD PASI score reduced to 2.6 ± 4.2 and remained low at year 1 (2.3 ± 4.3) through year 5 (1.4 ± 2.8). A higher proportion of patients who were biologic&#xa0;naïve and those with a shorter disease duration achieved PASI90 and PASI100 responses and demonstrated higher retention rates than those in patients previously treated with biologics and those with a longer disease duration. The safety profile was consistent with known data, with no new safety signals identified.</p> Conclusions <p>Secukinumab showed high treatment retention, sustained effectiveness, and a consistent safety profile up to 5&#xa0;years of follow-up in the real-world population of patients with PsO observed in SERENA.</p> <p>Graphical abstract available for this article.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月2日

查看全文
  • Matthias Augustin,
  • Paul-Gunther Sator,
  • Ralph von Kiedrowski,
  • Dimitris Rigopoulos,
  • Marco Romanelli,
  • Pierre-Dominique Ghislain,
  • Tiago Torres,
  • Dimitrios Ioannides,
  • Cynthia Vizcaya,
  • Andreas Clemens,
  • Weibin Bao,
  • Christelle C. Pieterse,
  • Barbara Schulz,
  • Piotr Jagiello,
  • Curdin Conrad

摘要

Introduction

Secukinumab has demonstrated sustained efficacy and a favorable safety profile in clinical trials, providing relief from psoriatic symptoms.

Objective

To assess the long-term, real-world retention, effectiveness, and safety of secukinumab in routine clinical practice for the treatment of moderate to severe plaque psoriasis (PsO).

Methods

SERENA (CAIN457A3403) is a longitudinal, observational study conducted at 438 sites and 19 countries for up to 5 years in adult patients with moderate to severe PsO, psoriatic arthritis, and ankylosing spondylitis. Patients received secukinumab treatment for ≥ 16 weeks before enrollment. This manuscript presents the 5-year data from the SERENA study in patients with moderate to severe PsO.

Results

Overall, 1740 patients (67.5% male), with a mean age of 48.3 years and mean body mass index of 28.8 kg/m2, were included in the analysis. The estimated secukinumab retention rates were 88.5%, 76.3%, 68.6%, 63.1%, and 58.5% at years 1, 2, 3, 4, and 5, respectively. For the 913 patients who discontinued the study, the most common reasons included lack of efficacy (25.4%), patient decision (7.6%), physician decision (5.5%), and loss to follow-up (4.8%). The mean ± standard deviation (SD) absolute Psoriasis Area and Severity Index (PASI) score was 21.1 ± 13.0 at treatment initiation (n = 1545). At enrollment, the mean ± SD PASI score reduced to 2.6 ± 4.2 and remained low at year 1 (2.3 ± 4.3) through year 5 (1.4 ± 2.8). A higher proportion of patients who were biologic naïve and those with a shorter disease duration achieved PASI90 and PASI100 responses and demonstrated higher retention rates than those in patients previously treated with biologics and those with a longer disease duration. The safety profile was consistent with known data, with no new safety signals identified.

Conclusions

Secukinumab showed high treatment retention, sustained effectiveness, and a consistent safety profile up to 5 years of follow-up in the real-world population of patients with PsO observed in SERENA.

Graphical abstract available for this article.

Graphical Abstract